The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies-Reference-Cited by-同舟云学术

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies

Published:2024-04 Issue: Volume:196 Page:104295
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Ferro Alessandra^ORCID,Marinato Gian Marco,Mulargiu Cristiana,Marino Monica,Pasello Giulia,Guarneri Valentina,Bonanno Laura^ORCID

Publisher

Elsevier BV

Reference218 articles.

1. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis;Zhang;Oncotarget,2016

2. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N. Engl. J. Med.,2009

3. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study;Douillard;Br. J. Cancer,2014

4. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

5. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial;Wu;Lancet Oncol.,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Binary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC;Scientific Reports;2024-08-09

2. New promises and challenges in the treatment of advanced non-small-cell lung cancer;The Lancet;2024-08

3. Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired EGFR 19Del/T790M/cis-C797S mutation resistance;Frontiers in Oncology;2024-06-06

4. Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors;Cancers;2024-05-23

5. circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC);Molecular Cancer;2024-05-07